5 Minutes with Carole Renouf
29 February 2016
What are you most excited about as you look towards leading MIA into the future?
Leadership for me is all about the fulfilment of potential. That’s my job – to help an organisation and its people achieve their greatest potential. I am excited about the wealth of potential at MIA. This is an organisation that, in the medical and scientific world, has already established a stellar reputation. Now it’s time to share that with other worlds, and invite them to be part of it and support it.
Why did you want to work with MIA and what are you hoping to achieve through your work?
Somehow, health and medical research has turned out to be my ‘space’. I think it’s because I believe health is our greatest asset. People with health problems –whatever these are - need the best possible treatments and care today, but they also need the promise that research brings – a better tomorrow. MIA is quite a unique organisation in that it brings together, on a daily basis, care and research for the betterment of people with melanoma and to prevent others getting melanoma. If together we can achieve those goals, I will be happy.
Where did you work before coming to MIA?
Before joining MIA, I worked at St Vincent’s, the National Breast Cancer Foundation and the Garvan Institute. I have always worked in the not for profit sector, although it was originally an unconscious rather than a conscious choice. I am interested in social change, so it’s a natural fit despite the many challenges – especially lack of resources.
What drives you as a CEO?
I don’t think leaders are born. I think they are made, and that they are made through confident humility and an openness to lifelong learning. I guess that defines me as a CEO.
It’s interesting to me that today, the ‘soft’ skills which I possess are now the ones that are most sought-after in CEOs. I always used to feel inadequate because the ‘hard’ skills (say, accounting or operations) were not my strengths. It feels good to know that the world has now caught up with the fact that the ability to inspire, unite, communicate and advocate counts!
What do you like to do in your spare time?
I live a very low key life outside of work. I am actually an introvert in an extrovert’s role, so I burn an enormous amount of energy at work. In my spare time I really need down time with no people around me and preferably outside enjoying nature. I love my daughter. I love the sea. I love animals. I love physical activity. I love travel (definitely not the journey but the destination). And I love reading, preferably crime fiction where every problem gets solved – unlike the real world!
Tell us something most people are surprised to learn about you?
I initiated and ran Australia’s first consensus conference. This is a fascinating Scandinavian method of equipping lay people to give informed advice to Governments about controversial issues in science, technology, education and more. It has often led to great changes in society and I am very proud to have introduced this methodology to Australia.
SAVE THE DATE:
We want to thank every member of Team Melanoma and everyone who donated to them. With your help, we are moving closer to our goal of zero deaths from melanoma!
Lauren O'Brien tells us why she's running for a cause close to her heart
MIA could not do what we do without the incredible support and effort of our community fundraisers. We’d like to highlight some of the wonderful events organised by our community in
An international study, led by researchers from Melanoma Institute Australia, QIMR Berghofer Medical Research Institute and The University of Sydney as part of the Australian Melanoma Genome Project, has discovered that a drug traditionally used to treat a
Researchers from Melanoma Institute Australia took centre stage at the American Society of Clinical Oncology Annual Meeting in Chicago. Results presented by MIA’s contingent have the potential to create better patient outcomes and change the way advanced melanoma
Today is International Clinical Trials Day – a day to recognise and thank the amazing people who conduct, organise, and coordinate clinical trials.
“I’m the age Emma was when she passed away. It almost feels
As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions
As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions in support of the PBS listing.
MIA had four winners in the 2017 Premiers Awards. Find out how winning has influenced their work over the past year.
Cancer Council awards Melanoma Institute Australia researchers funding for ground-breaking cancer research projects
Almost $9 million of new funding was awarded to 13 ground-breaking cancer research projects at the 2019 Cancer Council NSW Research Awards.
Georgina V. Long is co-medical director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research. She is the first woman president of the Society for Melanoma Research.
Quintessential Aussie girl and media personality Sophie Monk has been announced as a National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.
Australian researchers have for the first time identified specific cells and receptors in the immune system which predict how a patient will respond to treatment with immunotherapies, potentially paving the way for the development of personalised therapy for all cancer patients.
Melanoma March is thrilled to introduce Ricky as our official Principal Partner for 2019!
World record holder, Olympian and Australian swimming champion Cate Campbell has been announced as National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.
MIA's expertise was essential to a recent Nature publication spearheaded by Perth’s Telethon Kids Institute and The University of Melbourne.
MIA is delighted to be hosting the MD Anderson pathologist on his first ever trip to Australia.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for dabrafenib and trametinib.